alexa Statins Dangers and Kidney: A Need for Prescription Revision | OMICS International
ISSN: 2161-1025
Translational Medicine

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Statins Dangers and Kidney: A Need for Prescription Revision

Majid Malaki*

Tabriz Children’s Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

*Corresponding Author:
Majid Malaki
Tabriz Children’s Hospital
Tabriz University of Medical Sciences, Tabriz, Iran
Tel: + 98 411 5262250
Fax: + 98 411 5262280
E-mail: [email protected]

Received Date: August 18, 2017; Accepted Date: August 29, 2017; Published Date: September 08, 2017

Citation: Malaki M (2017) Statins Dangers and Kidney: A Need for Prescription Revision. Transl Med 7: 195. doi:10.4172/2161-1025.1000195

Copyright: © 2017 Malaki M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Translational Medicine

Letter to Editor

Dyslipedemia effects on renal include: glomerulosclerosis, vascular smooth muscle proliferation by macrophage infiltration, foam cell formation and cytokine secretion, all these mechanisms are similar to what happen in atherosclerotic vessel wall [1], and all these consequences convince us statins may be a renoprotective drug but in some studies statins side effects on kidney was shown in long term study with large size sample that revealed higher potency statins may be associated with higher rate of hospital admission because of acute renal failure [2] in another study it has been shown that renal side effects may be dose dependent with different hazardous risk among different statins types (1.3% at 40 mg of rosuvastatin) these effects cannot be considered as primary disease progression because these effects was not seen in other statins while in another study increase acute renal failure met in statins except for fluvastatin [3,4]. In a retrospective cohort study, Statins users had greater odds of acute kidney injury up to 30% and chronic kidney disease up to 36% and the authors suggested statins in long-term usage may show increase morbidity and mortality and increase incidence of CKD and diabetes mellitus due to statins usage [5]. Renal failure may occur in first 120 days of usage high potency statins: (≥ 10 mg rosuvastatin, ≥ 20 mg atorvastatin, and ≥ 40 mg simvastatin), this risk may be highest in the first year and remained high during first year of stopping treatment and then returned to normal 1-3 years after stopping treatment [2,4]. In ASUCA study renal function was evaluated more comprehensive and prospective, showed statins in mild to moderate dose cannot preventive for decrease GFR in 24 month in spite of controlling dyslipedima and GFR in patients who used statins dropped more than control group after 18th month of statins usage with or without LDL-C over 140 or using RASS group drug as a renoprotective agent [1]. Statin effects as preventive for CKD in patients with GFR under 60 and non-dialysis stage reviewed in a Cochrane Database Systemtic review in 2014 and showed Statin-related effects on stroke and kidney function were found to be uncertain and adverse effects of treatment are incompletely understood [6]. Statins cannot consider as a safe drug that prevent the harmful effects of dyslipidemia on kidney in short term or long term and should be remind JUPITAR trial [2] that show two years use of high dose statins in 450 case can prevent one death from vascular accidents, and we should justify benefits of high potency statins would outweigh the combined risk of acute kidney injury, rhabdomyolysis, and diabetes that enforce us to surveillance these side effects when we use statins.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 488
  • [From(publication date):
    August-2017 - Jul 23, 2018]
  • Breakdown by view type
  • HTML page views : 442
  • PDF downloads : 46

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7